KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$9.65 USD
-0.13 (-1.33%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $9.64 -0.01 (-0.10%) 4:38 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
KalVista Pharmaceuticals, Inc. [KALV]
Reports for Purchase
Showing records 21 - 40 ( 107 total )
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Oral Protease Inhibitor Advancement in HAE; Pivotal Phase 3 Positioned for 1Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY2Q22- Strong Pipeline Progress and Balance Sheet, Phase 3 Start in 1Q22
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Single Phase 3 KVD900 Study Start Expected in 1Q2022, to Support NDA
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
KalVista Continues to Progress Towards Phase 3 Start
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY1Q22 Update- FDA Meeting for KVD900 This Month & Other Programs Advance
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Phase 2 Prophylactic HAE Study to Begin in CAN, AUS, and UK During 3Q2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY4Q21 Update - Strong Cash Position With Key Milestones Expected in 3Q21
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
KVD900 Oral On-Demand Capability, With Near-Term Phase 3 Headway
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
KVD824 on Clinical Hold, KVD900 Remains on Track - Selloff Seems Overdone
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
KVD824 Phase 2 Trial Expected to Initiate 2Q21 and KVD900 Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY3Q21 Update - KalVista Accelerates Towards an Oral HAE Franchise
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z